Pharmafile Logo
Pharmafocus logo
Advanced Search
6123892769_1befc31f38_o

WellBe bracelet, mobile app to help manage stress

June 17, 2016
Medical Communications, Research and Development HealthTech, WellBe, app, stress, wearable technology

Adding to the growing list of healthcare applications, a new technology claims to have created the first anti-stress biofeedback bracelet …

News
merck

Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer

June 17, 2016
Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer

US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …

News

Final Nice appraisal says no to cystic fibrosis drug, Orkambi

June 17, 2016
Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …

News
roche_close

Roche gets a NICE knockback for melanoma drug, Cotellic

June 16, 2016
Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche

The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …

News
chemo-web

SMC recommends treatment for potentially fatal chemotherapy-related disease

June 16, 2016
Research and Development, Sales and Marketing Menarini, SMC, adneuric

The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …

News
alzheimers_web_credit_shutterstock

Chiasma cuts staff by 33% after FDA rejects rare disease drug, Mycapssa

June 16, 2016
Research and Development, Sales and Marketing FDA, chiasma, cutbacks, failure, workforce cuts

US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …

News
flag_-_union_flag

UK biotech in great shape, according to new industry report

June 16, 2016
Research and Development Europe, UK, biotech, uk bioindustry association

The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …

News
roche

Roche secures EU approval for Gazyvaro in new lymphoma indication

June 16, 2016
Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma

Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …

News
teva_copy

Teva returns rights to heart cell therapy to Mesoblast

June 16, 2016
Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III

Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …

News
trials

Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA

June 15, 2016
Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals

Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …

News
money_pills_2

Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals

June 15, 2016
Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure

Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …

News
sobi

Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder

June 15, 2016
Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi

Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …

News

FDA issues warnings on Janssen, AstraZeneca diabetes drugs

June 15, 2016
Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana

The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …

News
lilly_entrance_web

German Supreme Court grants Lilly appeal to block Alimta generics

June 15, 2016
Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly

Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …

News
actelion_logo

Actelion says blood pressure drug Uptravi now available in Germany

June 15, 2016
Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch

Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany.  The European Commission granted …

News

Novartis says to develop antimalarial treatment with Medicines for Malaria Venture

June 15, 2016
Research and Development, Sales and Marketing Novartis, antimalarial drug, drug trial

Swiss pharma major Novartis (NYSE: NVS) said it has partnered with Medicines for Malaria Venture (MMV) and the Bill & Melinda …

News
shirelabsus

Shire adds to gastrointestinal portfolio with Pfizer compound acquisition

June 14, 2016
Research and Development, Sales and Marketing Pfizer, Shire, acquisition, compound

Shire (LSE: SHP) has announced that it has acquired an investigational biologic for the treatment inflammatory bowel disease from Pfizer …

News
janssen_latest_logo_on_sign_closer

Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study

June 14, 2016
Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica

Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …

News
stocks3

Marinus says will stop developing adult focal onset seizure drug as Phase III trials fail; shares plunge

June 14, 2016
Manufacturing and Production, Research and Development Drug-Resistant Epilepsy, Marinus Pharmaceuticals, drug trial, ganaxolone

Shares in Marinus Pharmaceuticals (Nasdaq: MRNS) more than halved in value Monday after the company said it plans to stop …

News
merckincweb

MSD insulin glargine biosimilar meets primary endpoint in late-stage trials

June 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Merck, biosimilar, insulin, insuline glargine

MSD (NYSE: MRK), known as Merck in the US and Canada, has announced results from two Phase III studies evaluating …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026